Phanes Therapeutics

aka Phanes Therapeutics, Inc.

Phanes Therapeutics is a San Diego biotech whose bispecific antibodies pair a tumour antigen with an immune signal; peluntamig hits DLL3 and CD47 in small cell lung cancer and spevatamig hits Claudin 18.2 and CD47 in stomach and pancreatic cancer.

Phanes Therapeutics develops bispecific antibodies using its PACbody, SPECpair and ATACCbody platforms. Peluntamig (PT217) binds DLL3 and CD47 and has orphan and fast track designations in small cell lung cancer and neuroendocrine carcinomas; spevatamig (PT886) binds Claudin 18.2 and CD47 for gastric and pancreatic cancers; mavrostobart (PT199) is a CD73 antibody being tested with PD-1 blockade and chemotherapy. All three are in phase 1/2 trials.

Headquarters

San Diego, California, US

Scorecard

All companies

#240of 1181 companies, score 18

phase 1/2 +3
targets +8
modalities +4
registry trials +3

0 approved, 0 in phase 3, 3 earlier, 4 targets, 3 registry studies. Formula on the scorecards page.

Type

biotech

Website

www.phanestherapeutics.com/

Products

3top

Phase 2bispecific antibody

Peluntamig

Peluntamig is an experimental bispecific antibody from Phanes Therapeutics in phase 2 trials for non-small-cell lung cancer and neuroendocrine tumours, aimed at CD47 and DLL3.

Phase 2bispecific antibody

Spevatamig

Spevatamig is an experimental bispecific antibody from Phanes Therapeutics in phase 2 trials for gastric & gastro-oesophageal junction cancer, pancreatic ductal adenocarcinoma and biliary tract cancer, aimed at Claudin 18.2 and CD47.

Phase 2monoclonal antibody

Mavrostobart

Mavrostobart is an experimental monoclonal antibody from Phanes Therapeutics in phase 2 trials for non-small-cell lung cancer and pancreatic ductal adenocarcinoma, aimed at CD73 / adenosine axis.